SE0101980D0 - Pharmaceutical combination - Google Patents

Pharmaceutical combination

Info

Publication number
SE0101980D0
SE0101980D0 SE0101980A SE0101980A SE0101980D0 SE 0101980 D0 SE0101980 D0 SE 0101980D0 SE 0101980 A SE0101980 A SE 0101980A SE 0101980 A SE0101980 A SE 0101980A SE 0101980 D0 SE0101980 D0 SE 0101980D0
Authority
SE
Sweden
Prior art keywords
ethoxy
pharmaceutical combination
phenyl
propanoic acid
methanesulfonyloxyphenyl
Prior art date
Application number
SE0101980A
Other languages
English (en)
Inventor
Peter Oehman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0101980A priority Critical patent/SE0101980D0/sv
Publication of SE0101980D0 publication Critical patent/SE0101980D0/sv
Priority to EP02728300A priority patent/EP1404309B1/en
Priority to ES02728300T priority patent/ES2269686T3/es
Priority to EEP200300584A priority patent/EE200300584A/xx
Priority to KR10-2003-7015601A priority patent/KR20040008202A/ko
Priority to BR0210128-9A priority patent/BR0210128A/pt
Priority to PL02367891A priority patent/PL367891A1/xx
Priority to RU2003136154/15A priority patent/RU2003136154A/ru
Priority to IL15903302A priority patent/IL159033A0/xx
Priority to US10/478,798 priority patent/US20040152771A1/en
Priority to CNA028149394A priority patent/CN1535144A/zh
Priority to AT02728300T priority patent/ATE336993T1/de
Priority to PCT/SE2002/001038 priority patent/WO2002096402A1/en
Priority to SK1470-2003A priority patent/SK14702003A3/sk
Priority to EP06000170A priority patent/EP1666034A1/en
Priority to CZ20033234A priority patent/CZ20033234A3/cs
Priority to DE60214185T priority patent/DE60214185T2/de
Priority to MXPA03011005A priority patent/MXPA03011005A/es
Priority to JP2002592913A priority patent/JP2004532864A/ja
Priority to CA002448643A priority patent/CA2448643A1/en
Priority to HU0400946A priority patent/HUP0400946A3/hu
Priority to NO20035237A priority patent/NO20035237D0/no
Priority to ZA200309264A priority patent/ZA200309264B/en
Priority to IS7058A priority patent/IS7058A/is
Priority to CO03112108A priority patent/CO5540375A2/es
Priority to HK04105673A priority patent/HK1062813A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0101980A 2001-06-01 2001-06-01 Pharmaceutical combination SE0101980D0 (sv)

Priority Applications (26)

Application Number Priority Date Filing Date Title
SE0101980A SE0101980D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination
HU0400946A HUP0400946A3 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic acid and a biguanide drug
PCT/SE2002/001038 WO2002096402A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug
EP06000170A EP1666034A1 (en) 2001-06-01 2002-05-30 Pharmaceutical combination comprising a biguanide
EEP200300584A EE200300584A (et) 2001-06-01 2002-05-30 Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja biguaniidravimit
KR10-2003-7015601A KR20040008202A (ko) 2001-06-01 2002-05-30 (ｓ)-2-에톡시-3-[4-(2-｛4-메탄술포닐옥시페닐｝에톡시)페닐]프로판산 또는3-｛4-[2-(4-ｔ-부톡시카르보닐아미노페닐)에톡시]페닐｝-(ｓ)-2-에톡시 프로판산 및 비구아니드 약물을 포함하는약학 조합물
BR0210128-9A BR0210128A (pt) 2001-06-01 2002-05-30 Combinação farmacêutica, método de tratamento ou de prevenção de diabetes, método de tratamento da sìndrome de resistência à insulina, kit de partes, produto combinado, e, método de produção de um produto combinado
PL02367891A PL367891A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- 4-(2- 4-methane sulfonyl oxyphenyl ethoxy) phenyl] propanoic acid or 3- 4- 2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl -(s)-2-ethoxy propanoic acid and a biguanide drug
RU2003136154/15A RU2003136154A (ru) 2001-06-01 2002-05-30 Фармацевтическая комбинация, содержащая либо (s)-2-этокси-3-[4-(2-{4-метансульфонилоксифенил}этокси)фенил]-пропионовую кислоту, либо 3-{4-[2-(4-третбутоксикарбониламинофенил)этокси]фенил}-(s)-этоксипропионов ую кислоту и бигуанидное лекарственное средство
IL15903302A IL159033A0 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s) -2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl)ethoxy] phenyl}-(s) -2- ethoxy propanoic acid and a biguanide drug
US10/478,798 US20040152771A1 (en) 2001-06-01 2002-05-30 Pharmaceutical combination comprising either (s)-2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy car4bonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and biguanide drug
CNA028149394A CN1535144A (zh) 2001-06-01 2002-05-30 一种包含(s)-2-乙氧基-3-[4-(2-{4-甲磺酰基氧基苯基}乙氧基)苯基]丙酸或3-{4-[2-（4-叔丁氧基羰基氨基苯基）乙氧基]苯基}-（s）-2-乙氧基丙酸和双胍类药物的联合药物
AT02728300T ATE336993T1 (de) 2001-06-01 2002-05-30 Pharmazeutische kombination mit (s)-2-ethoxy-3-4- (2-4-methansulfonyloxyphenylethoxy) phenyl propansäure oder 3-4-2-(4-tert.- butoxycarbonylaminophenyl) ethoxyphenyl-(s)-2- ethoxypropansäure und einem biguanid-arzneimittel
EP02728300A EP1404309B1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- 4-(2- 4-methane sulfonyl oxyphenyl ethoxy) phenyl| propanoic acid or 3- 4- 2- (4-tert-butoxy carbonyl aminophenyl) ethoxy| phenyl -(s)-2-ethoxy propanoic acid and a biguanide drug
SK1470-2003A SK14702003A3 (sk) 2001-06-01 2002-05-30 Farmaceutická kombinácia obsahujúca buď kyselinu (S)-2-etoxy-3- [4-(2-{4-metánsulfonyloxyfenyl}-etoxy)fenyl]propánovú, alebo kyselinu 3-{4-[2-(4-terc-butoxykarbonylaminofenyl)etoxy]fenyl}- (S)-2-etoxypropánovú a biguanidové liečivo
ES02728300T ES2269686T3 (es) 2001-06-01 2002-05-30 Una combinacion farmaceutica que comprende acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil)etoxi)fenil)propanoico o acido 3-(4-(2-(4-terc-butoxicarbonilaminofenil)etoxi)fenil)-(s)-2-etoxipropanoico y un farmaco de biguanida.
CZ20033234A CZ20033234A3 (cs) 2001-06-01 2002-05-30 Farmaceutická kombinace
DE60214185T DE60214185T2 (de) 2001-06-01 2002-05-30 Pharmazeutische kombination mit (s)-2-ethoxy-3-4-(2-4-methansulfonyloxyphenylethoxy) phenyl propansäure oder 3-4-2-(4-tert.-butoxycarbonylaminophenyl) ethoxyphenyl-(s)-2-ethoxypropansäure und einem biguanid-arzneimittel
MXPA03011005A MXPA03011005A (es) 2001-06-01 2002-05-30 Una combinacion farmaceutica que comprende ya sea acido (s)-2- etoxi-3[4 (2-{4- metansulfonil oxifenil} etoxi)fenil] propanoico o acido 3-(4 -[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)- 2-etoxi propanoico y un faramco biguanida.
JP2002592913A JP2004532864A (ja) 2001-06-01 2002-05-30 （Ｓ）−２−エトキシ−３−［４−（２−｛４−メタンスルホニルオキシフェニル｝エトキシ）フェニル］プロパン酸または３−｛４−［２−（４−ｔｅｒｔ−ブトキシカルボニルアミノフェニル）エトキシ］フェニル｝−（Ｓ）−２−エトキシプロパン酸のいずれかおよびビグアニド剤を含む薬剤的組み合わせ
CA002448643A CA2448643A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug
NO20035237A NO20035237D0 (no) 2001-06-01 2003-11-25 Farmasöytisk kombinasjon omfattende enten (S) -2-etoksy-3-(4- (2- (4-metansulfonyloksyfenyl) etoksy) fenyl) propansyre eller 3- (4- (2- (4-tert-butoksykarbonylaminofenyl) etoksy) fenyl)
ZA200309264A ZA200309264B (en) 2001-06-01 2003-11-27 A pharmaceutical combination comprising either (S)-2-ethoxy-3-[4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-[ (4-tert-butoxy carbonyl aminophenyl) ethoxy]phenyl} -(S)-2-ethoxy propanoic acid and a biguanide drug.
IS7058A IS7058A (is) 2001-06-01 2003-11-28 Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf
CO03112108A CO5540375A2 (es) 2001-06-01 2003-12-23 Una combinacion farmaceutica que comprende uno cualquiera de acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil) etoxi) fenil)propanoico o acido 3-(4-(2-(4-tert- butoxicarbonilaminofenil)etoxi)fenil)-(s)-2-etoxi propanoico y un farmaco de biguanida
HK04105673A HK1062813A1 (en) 2001-06-01 2004-08-02 A pharmaceutical combination comprising either (s)-2-ethoxy-3- 4-(2- 4-methane sulfonyl oxyphenyl ethoxy) phenylÜ propanoic acid or 3-4-2- (4- tert-butoxy carbonyl aminophenyl) ethoxyÜ phenyl -(s)-2- ethoxy propanoic acid and a biguanide drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101980A SE0101980D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
SE0101980D0 true SE0101980D0 (sv) 2001-06-01

Family

ID=20284362

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101980A SE0101980D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination

Country Status (25)

Country Link
US (1) US20040152771A1 (sv)
EP (2) EP1404309B1 (sv)
JP (1) JP2004532864A (sv)
KR (1) KR20040008202A (sv)
CN (1) CN1535144A (sv)
AT (1) ATE336993T1 (sv)
BR (1) BR0210128A (sv)
CA (1) CA2448643A1 (sv)
CO (1) CO5540375A2 (sv)
CZ (1) CZ20033234A3 (sv)
DE (1) DE60214185T2 (sv)
EE (1) EE200300584A (sv)
ES (1) ES2269686T3 (sv)
HK (1) HK1062813A1 (sv)
HU (1) HUP0400946A3 (sv)
IL (1) IL159033A0 (sv)
IS (1) IS7058A (sv)
MX (1) MXPA03011005A (sv)
NO (1) NO20035237D0 (sv)
PL (1) PL367891A1 (sv)
RU (1) RU2003136154A (sv)
SE (1) SE0101980D0 (sv)
SK (1) SK14702003A3 (sv)
WO (1) WO2002096402A1 (sv)
ZA (1) ZA200309264B (sv)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
DK1145717T3 (da) * 2000-04-13 2004-08-02 Pfizer Prod Inc Synergistisk virkning af glyburid og milrinon

Also Published As

Publication number Publication date
CN1535144A (zh) 2004-10-06
CZ20033234A3 (cs) 2004-12-15
SK14702003A3 (sk) 2004-09-08
PL367891A1 (en) 2005-03-07
EP1404309B1 (en) 2006-08-23
ZA200309264B (en) 2005-02-28
BR0210128A (pt) 2004-06-08
WO2002096402A1 (en) 2002-12-05
EP1666034A1 (en) 2006-06-07
ES2269686T3 (es) 2007-04-01
IS7058A (is) 2003-11-28
ATE336993T1 (de) 2006-09-15
IL159033A0 (en) 2004-05-12
NO20035237D0 (no) 2003-11-25
CA2448643A1 (en) 2002-12-05
DE60214185T2 (de) 2007-07-19
DE60214185D1 (en) 2006-10-05
HK1062813A1 (en) 2004-11-26
US20040152771A1 (en) 2004-08-05
HUP0400946A2 (hu) 2004-08-30
EP1404309A1 (en) 2004-04-07
JP2004532864A (ja) 2004-10-28
EE200300584A (et) 2004-02-16
RU2003136154A (ru) 2005-02-10
HUP0400946A3 (en) 2007-11-28
MXPA03011005A (es) 2004-02-27
KR20040008202A (ko) 2004-01-28
CO5540375A2 (es) 2005-07-29

Similar Documents

Publication Publication Date Title
HRP20090229T1 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate
RU2006107653A (ru) Связующее вспомогательное вещество и приготовленная на его основе таблетка в форме капли
NO20022591D0 (no) Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre
NO20033584L (no) Bredspektrede 2-(substituert-amino)-benzotiazolsulfonamid-hiv- proteaseinhibitorer
BR0207509A (pt) Pirazolilpirimidinas
IS8224A (is) Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði
NO20003069L (no) 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin- 2,4-dion-maleinsyre-salt-hydrat som farmasøytikum
SE0101980D0 (sv) Pharmaceutical combination
SE0101981D0 (sv) Pharmaceutical combination
SE0101982D0 (sv) Pharmaceutical combination
IL172440A0 (en) Potassium or sodium salt of (-)-2-{[2-(4-hydroxyphenyl) ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid and their use in medicine
BRPI0418226A (pt) preparação de cloridrato r-5-(2-(2-(2-etoxifenoxietilamino) propil-2-metoxibenzenossulfonamida de alta pureza quìmica
RS52014B (sr) Nova so benzoilgvanidina
NO20000665L (no) 2-{3-[4-(2-t-Butyl-6-trifluormetyl-4-pyrimidinyl)-1- piperazinyl]propyltio}-4-pyrimidinol-fumarat
FI980508A0 (fi) 2-(3,5-difluorfenyl)-3-(4-(metylsulfonyl)fenyl)-2-cyklopenten-1-on anvaendbar som COX-2 inhibitor